Search

Bio Roundup: Pfizer's Future, CRISPR in Patients, Drug Imports & More

BIO ROUNDUP: PFIZER'S FUTURE, CRISPR IN PATIENTS, DRUG IMPORTS & MORE

Acquisitions made Pfizer what it is today: the world's biggest drug maker measured by revenue. But as the company maps its future,...

NOVARTIS' KYMRIAH HEAD JUMPS SHIP TO T-CELL BIOTECH ATARA AS ITS R&D CHIEF QUITS

Novartis has lost its head of oncology and lead for its global head, cell and gene therapy unit Pascal Touchon as he steps up to become...

 
 
 
CMS delays national coverage determination for CAR-T therapies

CMS DELAYS NATIONAL COVERAGE DETERMINATION FOR CAR-T THERAPIES

In a statement, the agency said that a decision on whether to have Medicare cover the cell therapies would not be issued Friday, but...

Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More

NOTES FROM THE JPM19 VORTEX: PRICE APOCALYPSE, CELGENE FALLOUT & MORE

[ Editor's note: Ben Fidler and Sarah de Crescenzo coauthored this report .] It is here, and then it is gone. But by the time everyone...

 
 
 
15 For '19: Key Clinical Data To Watch For Next Year

15 FOR '19: KEY CLINICAL DATA TO WATCH FOR NEXT YEAR

It can take decades and billions of dollars to develop a drug, and its fate-and often that of its developer-rests in the outcome of...

In-house CAR-T manufacturing preferable to outsourcing, execs say

IN-HOUSE CAR-T MANUFACTURING PREFERABLE TO OUTSOURCING, EXECS SAY

Keeping manufacturing close to home allows for greater flexibility, lower long-term costs and building up native manufacturing capability,...

 
 
 
Bio Roundup: A Gene Editing 1st, China Rises, Schenkein Steps Away

BIO ROUNDUP: A GENE EDITING 1ST, CHINA RISES, SCHENKEIN STEPS AWAY

If you're still recovering from a Labor Day hangover or busy searching for the identity of the anonymous writer of the anti-Trump op-ed...

 
 
 
A cutting-edge new cancer treatment has two different price tags - and it could be the future of how we pay for drugs

A CUTTING-EDGE NEW CANCER TREATMENT HAS TWO DIFFERENT PRICE TAGS - AND IT COULD BE THE FUTURE OF HOW WE PAY FOR DRUGS

A cutting-edge new cancer treatment from Novartis called Kymriah just got approved to treat more people with certain blood cancers...

Three Pricing Models That Address the High-Cost Gene, Cell Therapies

THREE PRICING MODELS THAT ADDRESS THE HIGH-COST GENE, CELL THERAPIES

Research in gene therapy and other areas in recent years has led to many significant advances in efforts to develop new curative therapies...

 
 
 
Bio Roundup: Biotech IPOs, Migraine Progress, Takeda Woos Shire & More

BIO ROUNDUP: BIOTECH IPOS, MIGRAINE PROGRESS, TAKEDA WOOS SHIRE & MORE

If the recent IPO activity seems to be on overdrive, it's not your imagination. The number of companies filing to go public in the...

At Seattle Children's, Another Piece of Ambitious CAR-T Plan in Place

AT SEATTLE CHILDREN'S, ANOTHER PIECE OF AMBITIOUS CAR-T PLAN IN PLACE

The researchers and doctors at Seattle Children's are embarking upon a complicated quest, involving multiple clinical studies of cutting-edge...

 
 
 
 
 
 
 
 
 
Kymriah and the CAR-T roller coaster

KYMRIAH AND THE CAR-T ROLLER COASTER

With the FDA approval of Novartis' CAR-T drug, get ready for a roller coaster ride involving a therapy class that has the potential...

Bio Roundup: CAR-T's Huge Week, Merck's ‘Pib Choice & More

BIO ROUNDUP: CAR-T'S HUGE WEEK, MERCK'S ‘PIB CHOICE & MORE

The far-out idea of reprogramming a patient's immune cells to fight cancer, known as CAR-T, entered the mainstream this week, and two...

 
 
 
A medical breakthrough that hacks genes to fight cancer just got approved, and it's the beginning of 'a big new field of medicine'

A MEDICAL BREAKTHROUGH THAT HACKS GENES TO FIGHT CANCER JUST GOT APPROVED, AND IT'S THE BEGINNING OF 'A BIG NEW FIELD OF MEDICINE'

The FDA approved the first-ever gene therapy in the US on Wednesday. The drug, called Kymriah , is a highly personalized cancer treatment...